Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response

References

• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Stam K, Groffen J, . Structural organization of the bcr gene and its role in the Ph’ translocation. Nature 1985;315: 758–761.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619–1630.
   PubMed Web of Science ®Google Scholar
• Hazlehurst LA, Bewry NN, Nair RR, . Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control 2009;16:100–107.
   PubMedGoogle Scholar
• Howlader N, Noone AM, Krapcho M, editors. SEER Cancer Statistics Review, 1975 - 2008, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2008/
   Google Scholar
• Baccarani M, Dreyling M. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v165–v167.
   PubMed Web of Science ®Google Scholar
• NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Chronic myelogenous leukemia (version 2.2012). © 2011 National Comprehensive Cancer Network, Inc. Available from: http://www.NCCN.org
   Google Scholar
• Cortes JE, Talpaz M, O’Brien S, . Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006;106:1306–1315.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, . Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S, . Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758–3765.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Castagnetti F, Gugliotta G, . Response definitions and European LeukemiaNet management recommendations. Best Pract Res Clin Haematol 2009;22:331–341.
   PubMed Web of Science ®Google Scholar
• Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010;3:47.
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F, . In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 2006;66:11314–11322.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, . AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94:1765–1769.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, . Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, . Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011;12:841–851.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, . Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol 2009;22:295–302.
   PubMed Web of Science ®Google Scholar
• Vigil CE, Griffiths EA, Wang ES, . Interpretation of cytogenetic and molecular results in patients treated for CML. Blood Rev 2010;25:139–146.
   Web of Science ®Google Scholar
• Pelz AF, Kroning H, Franke A, . High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements. Ann Hematol 2002;81:147–153.
   PubMed Web of Science ®Google Scholar
• Schoch C, Schnittger S, Bursch S, . Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16:53–59.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Lin F, Reiter A, . Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996;87:1549–1555.
   PubMed Web of Science ®Google Scholar
• Cross NC, Feng L, Chase A, . Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929–1936.
   PubMed Web of Science ®Google Scholar
• Hunt MR. Real time PCR tutorial. In: Hunt RC, editor. Microbiology and immunoloy on-line. Columbia: University of South Carolina School of Medicine; 2010. Available from: http://pathmicro.med.sc.edu/pcr/realtime-home.htm
   Google Scholar
• Gharabaghi F, Tellier R, Cheung R, . Comparison of a commercial qualitative real-time RT-PCR kit with direct immunofluorescence assay (DFA) and cell culture for detection of influenza A and B in children. J Clin Virol 2008;42:190–193.
   PubMed Web of Science ®Google Scholar
• Lima L, Bernal-Mizrachi L, Saxe D, . Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011;117:1245–1252.
   PubMed Web of Science ®Google Scholar
• Goh HG, Lin M, Fukushima T, . Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma 2011;52:896–904.
   PubMed Web of Science ®Google Scholar
• Branford S, Seymour JF, Grigg A, . BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR–ABL using strict sensitivity criteria. Clin Cancer Res 2007;13:7080–7085.
   PubMed Web of Science ®Google Scholar
• Shah N, Kantarjian H, Hochhaus A, . Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up. Blood 2010;116(Suppl. 1): Abstract 206.
   Google Scholar
• Sobrinho-Simoes M, Wilczek V, Score J, . In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116:1329–1335.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkwitz S, . Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-{alpha} in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634–1642.
   PubMed Web of Science ®Google Scholar
• Branford S, Fletcher L, Cross NC, . Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330–3338.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, . Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, . Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program 2006;211–218.
   PubMedGoogle Scholar
• White HE, Matejtschuk P, Rigsby P, . Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010;116:e111–e117.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, . Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2011 Dec 9. [Epub ahead of print]
   Google Scholar
• Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma 2008;49:610–614.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010;120:2254–2264.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Jones D, . Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009;113:6315–6321.
   PubMed Web of Science ®Google Scholar
• Marin D, Ibrahim AR, Lucas C, . Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232–238.
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Muller MC, Erben P, . Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients – a follow-up analysis of the German CML Study IV. Blood 2011;118(Suppl. 1): Abstract 783.
   Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, . Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141–1145.
   PubMed Web of Science ®Google Scholar
• Rea D, Rousselot P, Nicolini FE, . Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Abl transcripts: results from the French CML Group (FILMC). Blood 2011;118(Suppl. 1): Abstract 604.
   Google Scholar
• Marin D, Bazeos A, Mahon FX, . Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–2388.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program 2009;477–487.
   PubMedGoogle Scholar
• Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009;22: 355–365.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shan J, Jones D, . Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol 2009;27:3659–3663.
   PubMed Web of Science ®Google Scholar
• Press RD, Willis SG, Laudadio J, . Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009;114: 2598–2605.
   PubMed Web of Science ®Google Scholar
• Eliasson L, Clifford S, Barber N, . Exploring chronic myeloid leukemia patients’ reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res 2011;35:626–630.
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, . BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118:1208–1215.
   PubMed Web of Science ®Google Scholar
• Cortes J, Talpaz M, Bixby D, . A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood 2010;116(Suppl. 1): Abstract 210.
   Google Scholar